-
June 15, 2023
June 15, 2023 RK Pharma Completes Acquisition of VGYAAN Pharmaceuticals
-
March 8, 2023
March 8, 2023 - VGYAAN Pharmaceuticals Joins End Drug Shortages Alliance
-
March 6, 2023
March 6, 2023 - VGYAAN Pharmaceuticals Receives Tentative Approval from US FDA for Selexipag Tablets, Generic Equivalent to UPTRAVI®
-
February 15, 2022
Nailesh Bhatt, CEO of VGYAAN Pharmaceuticals interviewed by Mike Alkire, CEO of Premier Inc. on InsideOut Podcast discussing how VGYAAN is reinventing the way we think about generic drugs.
-
December 07, 2021
Premier Joint Venture with VGYAAN Pharmaceuticals Launches First Product
-
August 16, 2021
VGYAAN Pharmaceuticals Receives US FDA Product Approval for Carbamazepine Tablets USP, 200 mg, Generic Equivalent to TEGRETOL®
-
August 13, 2021
VGYAAN Pharmaceuticals Receives US FDA Approval for Leuprolide Acetate Injection, 14 mg/2.8 mL (1 mg/0.2 mL) Multi-Dose Vials, the Generic Equivalent to LUPRON®
-
July 28, 2021
VGYAAN Pharmaceuticals Receives US FDA Approval for Ursodiol Capsules USP, Generic Equivalent to ACTIGALL®
-
July 02, 2021
VGYAAN Pharmaceuticals Launches Clomipramine Hydrochloride Capsules, USP, the Generic Version of ANAFRANILTM
-
July 01, 2021
VGYAAN Pharmaceuticals Launches Nadolol Tablets, USP, the Generic Version of CORGARD®